BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

路透新闻 · Feb 21, 2018 06:29

Feb 20 (Reuters) - Soleno Therapeutics Inc (SLNO.O) :

* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME

* SOLENO THERAPEUTICS INC - MINUTES OF MEETING CONFIRMED FDA, CO ALIGNED ON ALL KEY ASPECTS OF CO'S PLANNED PHASE III CLINICAL TRIAL FOR DCCR

Source text for Eikon: Further company coverage: (SLNO.O)

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

Risk Disclaimer